Stockscreener 앱 받기
2.18
6.03%
-0.14
시간 외 거래:
2.28
0.10
+4.59%
전일 마감가:
$2.32
열려 있는:
$2.25
하루 거래량:
17,633
Relative Volume:
0.15
시가총액:
$10.97M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-15.18%
1개월 성능:
-4.80%
6개월 성능:
-60.72%
1년 성능:
+0.00%
1일 변동 폭
$2.10
$2.25
1주일 범위
$2.01
$2.6918
52주 변동 폭
$2.01
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
명칭
Traws Pharma Inc
전화
267-759-3680
주소
12 PENNS TRAIL, NEWTOWN
TRAW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.18 | 10.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-18 | 개시 | Guggenheim | Buy |
| 2018-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2017-10-09 | 개시 | H.C. Wainwright | Buy |
| 2017-04-27 | 개시 | Laidlaw | Buy |
| 2015-07-01 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | 개시 | H.C. Wainwright | Buy |
모두보기
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs - MSN
TRAW stock touches 52-week low at $2.01 amid sharp annual decline By Investing.com - Investing.com South Africa
TRAW stock touches 52-week low at $2.01 amid sharp annual decline - Investing.com India
Traws Pharma Reports 2024 Results and Strategic Progress - TipRanks
Traws Pharma Showcases Promising COVID-19 Drug at ICAR Conference - MSN
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost By Investing.com - Investing.com South Africa
Earnings call transcript: Traws Pharma Q1 2025 shows innovation boost - Investing.com
Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19 - MSN
Traws Pharma Reports 2024 Financial Results and CEO Change - TipRanks
Traws Pharma CEO Werner Cautreels to retire - MSN
Traws Pharma Reports Full Year 2024 Results and Business Highlights - GlobeNewswire
Traws Pharma's Bird Flu Drug Shows Promise Despite $166M Annual LossKey Updates - Stock Titan
Traws Pharma (TRAW) Expected to Announce Quarterly Earnings on Monday - Defense World
Traws Pharma Announces CEO Transition as Werner Cautreels Retires - MSN
Traws Pharma announces CEO retirement and interim successor By Investing.com - Investing.com South Africa
Traws Pharma announces CEO retirement and interim successor - Investing.com India
Traws Pharma CEO Werner Cautreels Retires, Chair Iain Duke Succeeds on Interim Basis - MarketScreener
Traws Pharma Announces Management Updates - GlobeNewswire
Leadership Shift at Traws Pharma: Chairman Steps Up as CEO Exits, Key Antiviral Programs Continue - Stock Titan
Traws Pharma Reports Promising Preclinical Results for Bird Flu Treatment - MSN
Traws Pharma Announces Promising Data for Ratutrelvir as a COVID-19 Treatment - MSN
Traws Pharma to Host Investor Event on Bird Flu and COVID - GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - Yahoo Finance
Former CDC Director Unveils Game-Changing Bird Flu and COVID Treatments at Traws Pharma Event - Stock Titan
Traws Pharma presents data on COVID-19 candidate ratutrelvir at ICAR - TipRanks
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment By Investing.com - Investing.com South Africa
Traws Pharma’s ratutrelvir shows promise in COVID-19 treatment - Investing.com
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewswire
Breakthrough: Next-Gen COVID Drug Defeats 18 Variants Without Ritonavir Boost - Stock Titan
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates - GlobeNewswire
Breakthrough: New Bird Flu Drug Achieves Remarkable 99.9% Viral Reduction in Latest Primate Tests - Stock Titan
Traws Pharma Unveils Promising Bird Flu Treatment Data - MyChesCo
Traws Pharma touts bird flu drug efficacy at ICAR By Investing.com - Investing.com South Africa
Traws Pharma touts bird flu drug efficacy at ICAR - Investing.com
Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - The Manila Times
Traws Pharma Presents Positive Data For TXM As Bird Flu Treatment At ICAR -March 21, 2025 at 07:03 am EDT - Marketscreener.com
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewswire
Breakthrough: Revolutionary Bird Flu Drug Achieves Perfect Survival Rate in Latest Trial Data - StockTitan
Traws Pharma Enters $50 Million ATM Agreement With Citizens JMP Securities -March 10, 2025 at 05:35 pm EDT - Marketscreener.com
Traws Pharma Announces Promising Preclinical Results for Bird Flu Treatment - MSN
PA-based biopharma company reports positive results testing efficacy of bird flu antiviral - Pennsylvania Business Report
TRAW stock touches 52-week low at $2.14 amid sharp annual decline - Investing.com
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Traws Pharma reports promising bird flu treatment results By Investing.com - Investing.com Canada
Traws Pharma reports promising bird flu treatment results - Investing.com India
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewswire
Can Traws Pharma's Single-Dose Treatment Combat the Growing Bird Flu Threat? - StockTitan
Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil - Marketscreener.com
Traws Pharma Inc (TRAW) 재무 분석
Traws Pharma Inc (TRAW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):